GLP-1 Insurance Denied? Here's What to Do Next (2026 Appeal Guide)

Last updated: June 9, 2026 · By GLP-1 Cost Finder Team

Your prescriber wrote the script, the pharmacy ran it through your insurance, and the answer came back: denied. If your gut reaction is "I guess I can't get this," stop there — that's the wrong answer. Most first-pass GLP-1 denials are automated decisions, not human reviews. They reverse all the time when you push back with the right paperwork.

The data backs this up: 30–50% of well-documented GLP-1 appeals succeed. That's not a guarantee — it depends on your plan, your indication, and how thoroughly your medical team documents the case — but it's a substantially better return than "give up and pay retail." This guide walks you through exactly what to do in the order that gets the highest hit rate.

And if your plan turns out to be one of the ones that won't budge no matter what you submit, the section at the end covers cash-pay options that have become dramatically cheaper than brand-name GLP-1s — in some cases, the all-in cash price is lower than what a covered patient pays in copays.

Why GLP-1 Claims Get Denied (And Why It's Rarely Final)

Insurance companies have algorithms that flag GLP-1 prescriptions for several specific reasons. Understanding which reason applies to you is the entire first step — the denial letter will tell you, and the appeal strategy depends on it.

The most common denial reasons

• Missing BMI documentation. Coverage typically requires BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, sleep apnea, cardiovascular disease, dyslipidemia). If your prescriber's note didn't include current BMI, the prior auth fails on a technicality.
• No documentation of prior weight-loss attempts. Most plans require evidence that you've tried lifestyle interventions — supervised diet programs, structured exercise plans, behavioral coaching — for at least 3–6 months without sufficient result. "I tried to eat better" is not enough; documented program names, durations, and outcomes are.
• Prior authorization form not submitted. Some prescribers skip the PA form and just write the prescription. The pharmacy then gets the denial. This is the easiest fix: ask the prescribing office to submit the PA.
• Blanket weight-loss exclusion. Some plans — especially self-funded employer plans — carry an explicit exclusion for any drug whose primary indication is weight management. If this is your reason, internal appeals will not succeed; you need a different strategy (see below).
• Drug not on formulary. Your plan may cover Ozempic for diabetes but not Wegovy for weight loss, even though both are semaglutide. Switching to the on-formulary equivalent for your indication often gets immediate approval.
• Coverage limited to specific indications. Several Medicare and Medicaid plans cover GLP-1s only for type 2 diabetes, not for weight management. If you were prescribed for weight loss alone, that may be why.

The denial letter is required to state the specific reason. Read it carefully before doing anything else. Whatever it says is what you must address in your appeal — not whatever you assume the reason was.

Step-by-Step: The Appeal Process That Works

Step 1 — Read the denial letter (and find the deadline)

Two pieces of information matter most: the specific denial reason (you'll address this in your appeal) and the appeal deadline, usually 30–60 days from the denial date. Miss the deadline and you start over. Put the deadline in your calendar today.

The letter will also tell you how to submit the appeal — usually a fax number, mailing address, or online portal — and what kind of appeal is available (internal, peer-to-peer, expedited). Note all of these.

Step 2 — Call your insurance company

Within the first few days, call the member services number on your insurance card. Ask specifically:

• "What exact documentation will reverse this denial?" — they will tell you, in concrete terms (e.g., "we need lab results from the last six months and documentation of a six-month supervised weight-loss program").
• "Is a peer-to-peer review available?" — this is a phone call between your prescriber and an insurance company medical director. Peer-to-peer reviews approve at much higher rates than written appeals when your prescriber is well prepared.
• "What's your fax number for the appeal?" — faxing often arrives faster than mail or portal uploads.

Take notes on names, reference numbers, and the date of the call. Insurance companies are required to honor what their reps tell you, but only if you can prove what was said.

Step 3 — Get a Letter of Medical Necessity from your prescriber

This is the single highest-leverage piece of the appeal. A well-written Letter of Medical Necessity (LMN) should include:

• Your current BMI, weight history (ideally with documented values over time), and any documented weight gain pattern.
• All obesity-related comorbidities: type 2 diabetes (with HbA1c), hypertension (with blood pressure readings), sleep apnea (with sleep study results if available), cardiovascular disease, dyslipidemia, fatty liver disease, etc.
• Prior weight-loss attempts: name the programs (Weight Watchers, Noom, supervised medical weight loss, prior medications like phentermine), duration, and outcomes.
• Clinical rationale for choosing this specific GLP-1 over alternatives.
• Reference to clinical evidence supporting GLP-1 efficacy for your indication — STEP trials for semaglutide (Wegovy), SURMOUNT trials for tirzepatide (Zepbound).
• The plan-specific criteria the letter is addressing — if the denial was for missing comorbidity documentation, the letter must explicitly state your qualifying comorbidities.

Many obesity-medicine specialists and primary care offices have template LMNs they can adapt for you. If yours doesn't, ask if the prescriber can refer you to an obesity-medicine specialist who does — the documentation discipline at those practices is generally stronger.

Step 4 — Submit your internal appeal

Internal appeals go to the insurance company itself. Include everything the call-center rep said you'd need, plus the LMN and supporting medical records. Submit via the fastest method available (typically fax with a confirmation page kept in your records).

Internal appeals usually get a written decision within 30 days, sometimes faster if you request an expedited review for a medication that's clinically urgent.

Step 5 — If the internal appeal fails, file an external appeal

If the insurance company denies your internal appeal, federal law gives you the right to an external appeal — review by an Independent Review Organization (IRO) selected by your state insurance department, not by the insurance company. The IRO reviewers are obesity medicine specialists and other independent clinicians; they are not paid by the insurer.

External appeals reverse internal denials at meaningful rates — particularly when the original denial was based on a technicality or when the medical necessity case is strong. The process is free for you, and the IRO's decision is binding on the insurance company.

Your denial letter (or your state insurance department's website) explains how to file. There is a deadline — usually 4 months from the final internal denial — so don't sit on it.

Step 6 — If you're on Medicare, check the Bridge Program

As of July 1, 2026, the Medicare GLP-1 Bridge Program began covering Wegovy, Zepbound (KwikPen), and Foundayo at a flat $50/month copay for qualifying beneficiaries. If you're enrolled in Medicare Part D and have a BMI ≥ 27 with a qualifying comorbidity, the Bridge may apply to you even if your specific Part D plan previously denied coverage. The program runs through December 31, 2027.

When Insurance Isn't Going to Cover It

Some denials are permanent — not because your medical case is weak, but because the underlying plan design excludes the medication entirely. The most common situations:

• Self-funded employer plans with weight-management exclusions. Self-funded plans (the employer pays claims directly; the insurance company just administers them) are governed by federal ERISA law, not state insurance mandates. Many of these plans carry blanket exclusions for any anti-obesity medication. No medical necessity argument overrides an explicit exclusion.
• Individual market plans without obesity coverage. Some marketplace and individual plans don't cover GLP-1s for weight loss as a covered benefit at all.
• Medicare Advantage plans that haven't opted into the Bridge. Most plans participate, but check yours directly.
• Plans that only cover diabetes-indicated GLP-1s. If you're prescribed Wegovy or Zepbound for weight management and your plan only covers Ozempic and Mounjaro for diabetes, the appeal probably won't fix that — the plan doesn't cover the indication.

Two pieces of context you might not have heard:

• Even with coverage, copays for brand-name GLP-1s can run $200–$500/month. Many "covered" patients end up paying more than smart cash-pay shoppers.
• The cash-pay market has shifted dramatically in 2026. Compounded GLP-1s through licensed telehealth providers have driven all-in prices well under $200/month — in several cases, under $150/month.

If insurance is a hard "no," cash-pay is no longer the expensive last resort it used to be.

Affordable Alternatives When You Pay Cash

Compounded GLP-1s through telehealth (the cheapest legitimate path)

Compounded semaglutide and tirzepatide contain the same active ingredients as brand-name Wegovy, Zepbound, Ozempic, and Mounjaro. They're prepared by FDA-registered compounding pharmacies (503A or 503B facilities) under a licensed prescriber's order. The legal status of compounded GLP-1s evolved through 2025–2026 as both medications came off the FDA shortage list, but licensed compounders can still serve individual patients with documented medical need on a per-prescription basis.

Typical 2026 pricing from verified telehealth providers:

• Oak — compounded semaglutide at $133/month flat, compounded tirzepatide at $199/month flat. No membership fee, no consultation fee, no shipping fee. Same price at every dose.
• FeelGood — compounded injections from $149/month, compounded tablets from $249/month. HSA/FSA approved.
• Liv Body — compounded semaglutide $179/month, tirzepatide $279/month. Includes Care Coach health-coaching layer.

For a deeper dive on how compounded GLP-1s compare to brand-name versions clinically and on cost, see our compounded semaglutide vs brand Wegovy guide.

Manufacturer savings cards and patient assistance

If you have commercial insurance and your plan covers the drug (just at a high copay), the manufacturer savings card from Novo Nordisk (Ozempic, Wegovy) or Eli Lilly (Mounjaro, Zepbound) often drops your copay to $25/month. If you're uninsured and income-qualified, the NovoCare and Lilly Cares Patient Assistance Programs may provide free medication. Our savings cards and PAP guide covers eligibility for every program.

Brand-specific cash-pay paths

• Wegovy: NovoCare self-pay channel + savings card stacking. See our cheapest Wegovy without insurance guide for current pricing.
• Zepbound and Mounjaro: LillyDirect direct-to-consumer pricing starts at $299/month for Zepbound starter doses. Compounded tirzepatide undercuts brand-name pricing significantly.

Use the comparison tool to see all real options

Pricing across telehealth providers updates monthly and varies meaningfully by medication, dose, and provider. Rather than guessing or trusting an outdated price list, run your situation against the live tool:

Compare all GLP-1 providers and prices →

Key Takeaways

• Don't accept the first denial. Most are automated decisions. 30–50% of well-documented appeals succeed.
• Read the denial letter and meet the deadline. The letter tells you exactly what to appeal and when. Miss the deadline and you start over.
• The Letter of Medical Necessity is the single most important document. Ask your prescriber for one, and make sure it covers BMI, comorbidities, prior attempts, and clinical rationale.
• If internal appeal fails, escalate to external appeal. Independent reviewers approve at meaningfully higher rates than the insurance company itself.
• If you're on Medicare, the new GLP-1 Bridge Program covers Wegovy, Zepbound (KwikPen), and Foundayo at $50/month for qualifying beneficiaries through December 31, 2027.
• If your plan permanently excludes coverage, cash-pay options have become genuinely affordable. Compounded GLP-1s through licensed telehealth providers start at $133/month all-in.